A NEW cancer alliance is launching this week to get a fairer deal for the many cancer sufferers who are missing out on new, lifesaving drugs because they can’t afford them.
The National Oncology Alliance, made up of clinicians, patients and pharmaceutical companies, plans to highlight the inequities that exist with patients and lobby the government for fairer treatment.
NOA is calling for changes ahead of the Pharmaceutical Benefits Advisory Committee meeting on Friday.
“It’s unfair. If you had twin brothers, one with melanoma and another with a rare skin cancer called merkle cell, and both were prescribed the same drug, the melanoma brother would pay $39 a month and the other would pay up to $10,000,” said co-chair of NOA Richard Vines, from Rare Cancers Australia.